Citadel Advisors
FENC icon

Citadel Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Citadel Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,400
Closed -$182K – 14592
2024
Q1 		$182K Buy
16,400
+6,600
+67% +$66.3K ﹤0.01% 10463
2023
Q4 		$110K Sell
9,800
-3,100
-24% -$25.7K ﹤0.01% 10813
2023
Q3 		$96.9K Sell
12,900
-47,300
-79% -$385K ﹤0.01% 10942
2023
Q2 		$532K Sell
60,200
-33,300
-36% -$277K ﹤0.01% 7805
2023
Q1 		$778K Sell
93,500
-53,600
-36% -$497K ﹤0.01% 7340
2022
Q4 		$1.41M Buy
147,100
+108,100
+277% +$957K ﹤0.01% 6162
2022
Q3 		$316K Buy
+39,000
New +$268K ﹤0.01% 9459
2021
Q3 		– Sell
-11,400
Closed -$83K – 14026
2021
Q2 		$83K Buy
+11,400
New +$76.1K ﹤0.01% 13052
2020
Q4 		– Sell
-13,500
Closed -$82K – 11083
2020
Q3 		$82K Sell
13,500
-5,600
-29% -$39.5K ﹤0.01% 9379
2020
Q2 		$159K Buy
19,100
+8,500
+80% +$63.2K ﹤0.01% 8702
2020
Q1 		$63K Buy
+10,600
New +$69.1K ﹤0.01% 8912

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Citadel Advisors's FENC Position: Q1 2026 in Review

Citadel Advisors reduced its Fennec Pharmaceuticals (FENC) stake by 23% in Q1 2026, selling an estimated $356K and leaving 153,610 shares worth $945K. The position accounts for ﹤0.01% of the portfolio, ranked #7789.

Citadel Advisors first reported a position in FENC in Q4 2021 and has held it in 11 quarters since. The position peaked at $1.54M in Q4 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Citadel Advisors held 153,610 shares of Fennec Pharmaceuticals worth $945K as of Q1 2026.
  • Citadel Advisors sold 46,139 Fennec Pharmaceuticals shares in Q1 2026, an estimated $356K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7789 holding.
  • Citadel Advisors first reported a position in Fennec Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
  • Citadel Advisors's Fennec Pharmaceuticals position peaked at $1.54M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.